Subcutaneous Immunotherapy (SCIT) with the New Polymerized Molecular Allergoid Alt a1 : A Pilot Study in Children with Allergic Rhinitis Sensitized to Alternaria Alternata
BACKGROUND: We followed the effects of a new SCIT with a chemically polymerized allergen Alt a1, evaluating the trend of clinical and functional parameters in an observational-prospective study.
METHODS: 42 children with AR and intermittent asthma sensitized to A.A.: 17 patients started SCIT (Modigoid®), and 25 continued symptomatic therapy. At the initial visit (T0), all patients performed total IgE (tIgE) and specific IgE (sIgE) for Alt a1, nasal nitric oxide (nFeNo), nasal cytology, anterior active rhinomanometry (AAR) and spirometry. After 24 months (T1), they repeated the same procedures as in T0.
RESULTS: Patients treated with Modigoid presented a statistically significant (p < 0.001) reduction of nFeNO (T0:1651.06 ± 149.18; T1: 1394.12 ± 108.98), tIgE (T0: 311.48 ± 144.18; T1: 164.73 ± 50.69), sIgE for Alt a1 (T0: 28.59 ± 12.69; T1: 19.54 ± 7.37), an improvement of nasal airflow (T0: 71.62 ± 8.66; T1: 95.12 ± 5.91), nasal eosinophils (T0: 20.59 ± 2.35; T1: 14.88 ± 1.65) and FEV1 (T0: 95.58 ± 7.91; T1: 116.64 ± 5.94).
CONCLUSIONS: The new SCIT for Alt a1 significantly improves AR symptoms from a subjective, objective point of view and laboratory and functional parameters.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 13 vom: 27. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brindisi, Giulia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergic rhinitis (AR) |
|---|
| Anmerkungen: |
Date Revised 18.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm12134327 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359461077 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359461077 | ||
| 003 | DE-627 | ||
| 005 | 20231226080926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12134327 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359461077 | ||
| 035 | |a (NLM)37445362 | ||
| 035 | |a (PII)4327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brindisi, Giulia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Subcutaneous Immunotherapy (SCIT) with the New Polymerized Molecular Allergoid Alt a1 |b A Pilot Study in Children with Allergic Rhinitis Sensitized to Alternaria Alternata |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: We followed the effects of a new SCIT with a chemically polymerized allergen Alt a1, evaluating the trend of clinical and functional parameters in an observational-prospective study | ||
| 520 | |a METHODS: 42 children with AR and intermittent asthma sensitized to A.A.: 17 patients started SCIT (Modigoid®), and 25 continued symptomatic therapy. At the initial visit (T0), all patients performed total IgE (tIgE) and specific IgE (sIgE) for Alt a1, nasal nitric oxide (nFeNo), nasal cytology, anterior active rhinomanometry (AAR) and spirometry. After 24 months (T1), they repeated the same procedures as in T0 | ||
| 520 | |a RESULTS: Patients treated with Modigoid presented a statistically significant (p < 0.001) reduction of nFeNO (T0:1651.06 ± 149.18; T1: 1394.12 ± 108.98), tIgE (T0: 311.48 ± 144.18; T1: 164.73 ± 50.69), sIgE for Alt a1 (T0: 28.59 ± 12.69; T1: 19.54 ± 7.37), an improvement of nasal airflow (T0: 71.62 ± 8.66; T1: 95.12 ± 5.91), nasal eosinophils (T0: 20.59 ± 2.35; T1: 14.88 ± 1.65) and FEV1 (T0: 95.58 ± 7.91; T1: 116.64 ± 5.94) | ||
| 520 | |a CONCLUSIONS: The new SCIT for Alt a1 significantly improves AR symptoms from a subjective, objective point of view and laboratory and functional parameters | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alt a1 | |
| 650 | 4 | |a Alternaria Alternata | |
| 650 | 4 | |a Modigoid | |
| 650 | 4 | |a allergic rhinitis (AR) | |
| 650 | 4 | |a anterior active rhinomanometry (AAR) | |
| 650 | 4 | |a children | |
| 650 | 4 | |a nasal FeNO (nFeNO) | |
| 650 | 4 | |a nasal citology | |
| 650 | 4 | |a precision medicine | |
| 650 | 4 | |a subcutaneus immunotherapy | |
| 700 | 1 | |a Gori, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Anania, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Martinelli, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Capponi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a De Castro, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Zicari, Anna Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 13 vom: 27. Juni |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:13 |g day:27 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12134327 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 13 |b 27 |c 06 | ||